Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew B Lassman

Showing results (61-70 of 145) with videos related to

Pageof 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2009
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastomaJennifer L Clarke, Fabio M Iwamoto, Joohee Sul, et al.
Neurology|November 19, 2021
Causes of Death and End-of-Life Care in Patients With Intracranial High-Grade Gliomas: A Retrospective Observational StudyMarissa Barbaro, Craig D Blinderman, Fabio M Iwamoto, et al.
Clinical Trials (London, England)|February 4, 2020
Discordant attitudes and beliefs about cancer clinical trial participation between physicians, research staff, and cancer patientsGrace C Hillyer, Melissa Beauchemin, Dawn L Hershman, et al.
Ophthalmic Research|May 31, 2023
A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab MafodotinColin J Vize, Stella K Kim, Tim Matthews, et al.
Journal of Neuro-Oncology|June 29, 2011
Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomasFabio M Iwamoto, Andreas F Hottinger, Sasan Karimi, et al.
Neuro-Oncology|August 12, 2011
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomasFabio M Iwamoto, Andreas F Hottinger, Sasan Karimi, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2017
Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic AstrocytomaJennifer Clarke, Elizabeth Neil, Robert Terziev, et al.
Journal of Neuro-Oncology|August 3, 2015
Control of brain metastases from radioresistant tumors treated by stereotactic radiosurgeryAndrew Yaeh, Tavish Nanda, Ashish Jani, et al.
Annals of Neurology|March 11, 2011
YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphomaAndreas F Hottinger, Fabio M Iwamoto, Sasan Karimi, et al.
Neurology|April 8, 2020
Preparing a neurology department for SARS-CoV-2 (COVID-19): Early experiences at Columbia University Irving Medical Center and the New York Presbyterian Hospital in New York CityGenna Waldman, Richard Mayeux, Jan Claassen, et al.
Pageof 15

Showing results (61-70 of 145) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 10, 2009
Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastomaJennifer L Clarke, Fabio M Iwamoto, Joohee Sul, et al.
Neurology|November 19, 2021
Causes of Death and End-of-Life Care in Patients With Intracranial High-Grade Gliomas: A Retrospective Observational StudyMarissa Barbaro, Craig D Blinderman, Fabio M Iwamoto, et al.
Clinical Trials (London, England)|February 4, 2020
Discordant attitudes and beliefs about cancer clinical trial participation between physicians, research staff, and cancer patientsGrace C Hillyer, Melissa Beauchemin, Dawn L Hershman, et al.
Ophthalmic Research|May 31, 2023
A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab MafodotinColin J Vize, Stella K Kim, Tim Matthews, et al.
Journal of Neuro-Oncology|June 29, 2011
Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomasFabio M Iwamoto, Andreas F Hottinger, Sasan Karimi, et al.
Neuro-Oncology|August 12, 2011
Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomasFabio M Iwamoto, Andreas F Hottinger, Sasan Karimi, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2017
Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic AstrocytomaJennifer Clarke, Elizabeth Neil, Robert Terziev, et al.
Journal of Neuro-Oncology|August 3, 2015
Control of brain metastases from radioresistant tumors treated by stereotactic radiosurgeryAndrew Yaeh, Tavish Nanda, Ashish Jani, et al.
Annals of Neurology|March 11, 2011
YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphomaAndreas F Hottinger, Fabio M Iwamoto, Sasan Karimi, et al.
Neurology|April 8, 2020
Preparing a neurology department for SARS-CoV-2 (COVID-19): Early experiences at Columbia University Irving Medical Center and the New York Presbyterian Hospital in New York CityGenna Waldman, Richard Mayeux, Jan Claassen, et al.
Pageof 15